Management ChangeApr 9, 2026, 05:07 PM
NovoCure Appoints Uri Weinberg as Chief Medical Officer, Increases Salary by CHF 5,000 Monthly
AI Summary
NovoCure Limited has appointed Uri Weinberg, M.D., Ph.D., as its Chief Medical Officer, effective April 8, 2026. Dr. Weinberg will assume this new role in addition to his existing responsibilities as Chief Innovation Officer. In connection with this expanded role, his monthly salary will increase by CHF 5,000, as outlined in a letter agreement dated April 7, 2026. This move reflects the company's strategic alignment of its medical and innovation leadership under a single executive, potentially streamlining decision-making in clinical development and product strategy.
Key Highlights
- Uri Weinberg, M.D., Ph.D., was appointed Chief Medical Officer of NovoCure Limited on April 8, 2026.
- Dr. Weinberg will retain his current position as Chief Innovation Officer, combining both leadership roles.
- His monthly salary will increase by CHF 5,000 as long as he remains in the Chief Medical Officer role.
- The compensation adjustment was formalized through a letter agreement dated April 7, 2026, with a company affiliate.
Price Impact
More from NVCR